BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li XX, Zhang F. Targeting TREM2 for Parkinson's Disease: Where to Go? Front Immunol 2021;12:795036. [PMID: 35003116 DOI: 10.3389/fimmu.2021.795036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ossola B, Rifat A, Rowland A, Hunter H, Drinkall S, Bender C, Hamlischer M, Teall M, Burley R, Barker DF, Cadwalladr D, Dickson L, Lawrence JMK, Harvey JRM, Lizio M, Xu X, Kavanagh E, Cheung T, Sheardown S, Lawrence CB, Harte M, Brough D, Madry C, Matthews K, Doyle K, Page K, Powell J, Brice NL, Bürli RW, Carlton MB, Dawson LA. Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome. Neuropharmacology 2023;224:109330. [PMID: 36375694 DOI: 10.1016/j.neuropharm.2022.109330] [Reference Citation Analysis]
2 Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology 2022. [DOI: 10.1016/j.pneurobio.2022.102270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]